Abby Hardy, Author at BioTuesdays

Markets

HCW assumes coverage of IsoRay at buy; PT 70 cents

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...

January 28, 2019

Markets

Analyst reminds investors about Profound Medical’s BPH opportunity

In a new report, Alliance Global Partners analyst Ben Haynor writes that investors appear to have ignored the potential of Profound Medical’s (OTCQX:PRFMF; TSX:PRN) TULSA-PRO MRI-guided ablation system for the treatment...

January 23, 2019

Developments

Blood protein may predict progression of pre-symptomatic Alzheimer’s disease

Researchers in Germany have identified a blood protein marker that can predict the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). The test can detect thisbiomarker in the blood up to 16...

January 23, 2019

Executive Moves

Ocutrx Vision names Dr. Linda Lam as chief scientific and strategy officer

Closely-held Ocutrx Vision Technologies appointed Dr. Linda Lam as chief scientific and strategy officer to guide new technology development, and help align current and future R&D efforts, industry trends and growth...

January 16, 2019

Markets

Piper Jaffray starts Canopy Growth at OW; PT $40

Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

January 9, 2019

Markets

HCW starts Unum Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Unum Therapeutics (NASDAQ:UMRX) with a “buy” rating and $18 price target. The stock closed at $4.47 on Dec. 19.

December 21, 2018

Markets

Mackie sets $10.50 PT for Medexus Pharma after reverse split

Mackie Research Capital established a price target of $10.50 for Medexus Pharmaceuticals (TSXV:MDP) following a 15-for-one reverse stock slated for completion on Dec. 19. Medexus, formerly Pediapharm (TSXV:PDP) also...

December 18, 2018

Markets

Roth starts CollPlant at buy; PT $7

Roth Capital Markets launched coverage of CollPlant Holdings (NASDAQ:CLGN) with a “buy” rating and 12-month price target of $7. The stock closed at $4.36 on Dec. 17. CollPlant is the world’s first and only commercial...

December 18, 2018

Markets

AGP starts DarioHealth at buy; PT $2.50

AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...

December 13, 2018

Developments

Research finds cancer detection in 10-minute blood test

Researchers in Australia have developed a simple blood test they claim can diagnose cancer in 10 minutes by identifying a unique DNA signature present in all types of the disease. While the test has yet to be studied in...

December 6, 2018

Author - Abby Hardy

HCW assumes coverage of IsoRay at buy; PT 70 cents

Analyst reminds investors about Profound Medical’s BPH opportunity

Blood protein may predict progression of pre-symptomatic Alzheimer’s disease

Ocutrx Vision names Dr. Linda Lam as chief scientific and strategy officer

Piper Jaffray starts Canopy Growth at OW; PT $40

HCW starts Unum Therapeutics at buy; PT $18

Mackie sets $10.50 PT for Medexus Pharma after reverse split

Roth starts CollPlant at buy; PT $7

AGP starts DarioHealth at buy; PT $2.50

Research finds cancer detection in 10-minute blood test

Subscribe